XtalPi operates at the intersection of artificial intelligence and drug discovery, focusing on biologics and antibody therapeutics. The company leverages advanced AI algorithms and deep learning techniques to analyze large, complex datasets, aiming to uncover hidden principles that can drive innovation in drug discovery. XtalPi serves pharmaceutical companies and biotech firms, providing technology and services that accelerate the development of new drugs. The company operates in the global pharmaceutical market, with key operations in Beijing, Shenzhen, and Shanghai, China. Its business model revolves around offering AI-powered solutions and services that enhance the efficiency and effectiveness of drug discovery processes. XtalPi generates revenue through partnerships, collaborations, and service agreements with major pharmaceutical companies, including a notable collaboration with Pfizer to accelerate the development of the COVID-19 oral antiviral drug PAXLOVID.

Keywords: AI, biologics, antibody therapeutics, drug discovery, deep learning, big data, pharmaceutical, biotech, innovation, Pfizer.